Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FQPY0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,740
Award facts
- Contract value 100% obligated
- $19,740.25 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $19,740.25 to DMS Pharmaceutical Group Inc. for Xolair 150 mg/ml syringes, with an ultimate completion date of January 9, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected under a firm fixed-price contract with no set-aside designation. The award was issued without any identified subcontractors, with the company serving as the prime and sole contractor responsible for delivery to Park Ridge, Illinois.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which carries a ceiling value of $499.9 million through December 31, 2036. The PPV-G GEN V program is part of the DLA's broader $30.3 billion acquisition strategy designed to provide a comprehensive range of pharmaceutical products and medical consumables to support Department of Defense military healthcare facilities worldwide. Xolair, an immunosuppressant biologic agent, represents one component of DMS Pharmaceutical Group's extensive product portfolio supporting federal pharmaceutical supply chain requirements across multiple therapeutic categories.
Quick answers
Who was awarded contract SPE2DR26FQPY0?
SPE2DR26FQPY0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 17, 2025.
How much is contract SPE2DR26FQPY0 worth?
The government has obligated $19,740 on SPE2DR26FQPY0.
Is contract SPE2DR26FQPY0 an order under another contract?
Yes. SPE2DR26FQPY0 is a delivery order under SPE2DR25D9331, an indefinite delivery contract.
Was contract SPE2DR26FQPY0 competed?
The extent of competition for SPE2DR26FQPY0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award